A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
Clinical trial NCT06741397 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06741397
- Sponsor
- ViiV Healthcare
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-20
- Primary completion
- 2026-09-09
- Enrollment
- 229
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.